DE69722608D1 - Hsv-mutant-1716 zur behandlung von mesotheliomen - Google Patents

Hsv-mutant-1716 zur behandlung von mesotheliomen

Info

Publication number
DE69722608D1
DE69722608D1 DE69722608T DE69722608T DE69722608D1 DE 69722608 D1 DE69722608 D1 DE 69722608D1 DE 69722608 T DE69722608 T DE 69722608T DE 69722608 T DE69722608 T DE 69722608T DE 69722608 D1 DE69722608 D1 DE 69722608D1
Authority
DE
Germany
Prior art keywords
mutant
mesotheliomas
hsv
treating
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69722608T
Other languages
English (en)
Other versions
DE69722608T2 (de
Inventor
Susanne Moira Brown
Alasdair Roderick Maclean
Nigel William Fraser
Bruce Paul Randazzo
Steven Albelda
Larry Kaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Wistar Institute of Anatomy and Biology
Original Assignee
University of Glasgow
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601507.8A external-priority patent/GB9601507D0/en
Priority claimed from GBGB9623365.5A external-priority patent/GB9623365D0/en
Application filed by University of Glasgow, Wistar Institute of Anatomy and Biology filed Critical University of Glasgow
Publication of DE69722608D1 publication Critical patent/DE69722608D1/de
Application granted granted Critical
Publication of DE69722608T2 publication Critical patent/DE69722608T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
DE69722608T 1996-01-25 1997-01-27 Hsv-mutant-1716 zur behandlung von mesotheliomen Expired - Lifetime DE69722608T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9601507.8A GB9601507D0 (en) 1996-01-25 1996-01-25 Treatment of non-neuronal cancer using HSV mutant
GB9601507 1996-01-25
GBGB9623365.5A GB9623365D0 (en) 1996-11-09 1996-11-09 Non-neuronal cancer treatment
GB9623365 1996-11-09
PCT/GB1997/000232 WO1997026904A1 (en) 1996-01-25 1997-01-27 Treatment of non-neuronal cancer using hsv mutant

Publications (2)

Publication Number Publication Date
DE69722608D1 true DE69722608D1 (de) 2003-07-10
DE69722608T2 DE69722608T2 (de) 2004-04-29

Family

ID=26308525

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69722608T Expired - Lifetime DE69722608T2 (de) 1996-01-25 1997-01-27 Hsv-mutant-1716 zur behandlung von mesotheliomen

Country Status (6)

Country Link
US (3) US20050226850A1 (de)
EP (2) EP0895476B1 (de)
AT (1) ATE241994T1 (de)
AU (1) AU1550797A (de)
DE (1) DE69722608T2 (de)
WO (1) WO1997026904A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
EP1061806A4 (de) * 1998-03-12 2001-09-12 Univ Pennsylvania Produktive zellen für replikationsselektive viren zur behandlung bösartiger erkrankungen
DE60039730D1 (de) * 1999-02-05 2008-09-11 Arch Dev Corp Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
DE60026554T2 (de) 1999-09-17 2006-09-28 Wellstat Biologics Corp. Onkolytisches vesicular stomatitis virus
AU2695101A (en) 2000-01-21 2001-07-31 Biovex Ltd Virus strains
RU2362584C2 (ru) 2003-03-07 2009-07-27 Робартс Рисерч Инститьют Применение вируса миксомы для терапевтического лечения рака и хронической вирусной инфекции
NZ542902A (en) 2003-03-27 2007-06-29 Ottawa Health Research Inst Mutant vesicular stomatitis viruses and use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
EP1694852B1 (de) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
EP2388315B1 (de) 2005-03-07 2014-05-21 The University of Western Ontario Verwendung von einem funktionelle M135R Proteine nicht-exprimierenden Myxom-Virus zur therapeutischen Behandlung
CA2847786C (en) 2005-05-03 2017-07-04 Ruth E. Martin An oral device and kit for use in association therewith
CN105769931B (zh) 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
CN105126210B (zh) 2008-04-15 2018-06-12 特鲁德尔医学国际公司 吞咽空气脉冲疗法口器及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
WO1993019591A1 (en) * 1992-03-31 1993-10-14 Arch Development Corporation Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
CA2234060A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen

Also Published As

Publication number Publication date
EP1314430A1 (de) 2003-05-28
ATE241994T1 (de) 2003-06-15
US20050226850A1 (en) 2005-10-13
US20110195053A1 (en) 2011-08-11
EP0895476A1 (de) 1999-02-10
US20070292394A1 (en) 2007-12-20
AU1550797A (en) 1997-08-20
WO1997026904A1 (en) 1997-07-31
DE69722608T2 (de) 2004-04-29
EP0895476B1 (de) 2003-06-04

Similar Documents

Publication Publication Date Title
DE69722608D1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
NO20003230L (no) Inhibering av RAF-kinase ved anvendelse av symmetrisk og usymmetrisk substituerte difenylureaforbindelser
ATE236262T1 (de) Rekombinanter schweinepocken-virus
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
DE59409565D1 (de) Verfahren zur Verbesserung der Sicherheit von Frankiermaschinen
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
CY1106223T1 (el) Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69527204D1 (de) Behandlung von krebs durch verwendung von hsv-mutanten
ATE228502T1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
NO20002504D0 (no) Adenovirusvektorer og fremgangsmÕte for Õ redusere homologe rekombinasjonsfenomener
ES2127396T3 (es) Inhibidores aromaticos de acetilcolinesterasa.
DK0684951T3 (da) Silylerede acetylcholinesterase-inhibitorer
DE69433978D1 (de) Methode der spezifischen abschaltung von genen durch dna-methylierung
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
DE3880453D1 (de) Vorwaermung von kohlenwasserstoff/wasserdampf-gemischen.
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
ATE220557T1 (de) Darmprotozoen-impfstoffe
ATE178654T1 (de) Impstoff zum schutze von pferden gegen pferdeherpesvirus-infektionen
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE184893T1 (de) Verwendung von enaminen als vulkanisationsbeschleuniger
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
ATE9579T1 (de) Substituierte benzonitrile und zusammensetzungen zum hemmen von viren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition